News | October 09, 2024
Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Subscribe To Our Newsletter & Stay Updated
